Abstract. The purpose of the present work was to study the effect of a methionine-enkephalin analogue on glucose tolerance in man. Groups of 5 to 8 normal subjects were given a 0.5 mg im injection of the drug or placebo just before a 100 g oral glucose load or a 0.5 g/kg iv glucose load. In the enkephalin analogue treated subjects, diminished insulin response to glucose was observed following the oral glucose load, with insulin values significantly lower than in the controls from time 10 to 90 min, but no corresponding change in the glucose curve. This effect was not observed when glucose was given iv in another group of 5 subjects in whom the significant blunting of the insulin response was accompanied by a significant decrease in glucose tolerance. These observations demonstrate that in man, enkephalin produces a decrease in insulin secretion in response to both oral and iv glucose loads. The absence of any marked impairment in glucose tolerance in the oral test in spite of the decreased insulin response suggests that enkephalin might have an additional effect in delaying glucose absorption.
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On the basis of their recent studies (Pyke & Leslie 1978 ; Leslie & Pyke 1978; Leslie et al. 1979) suggested that a genetically determined hypersensitivity to enkephalin might play a role in the genesis of some cases of non-insulin-dependent diabetics. Previous studies have already demon¬ strated the hyperglycaemic effects of opiates, by (Feldberg & Shaligram 1972; Feldberg & Gupta 1974 (Lord et al. 1977) . The effects of ß-endorphin and morphine, µ-receptors ago¬ nists, have been shown to be stimulatory (Ipp et al. 1978; Kanter et al. 1980 ) while those of enkephalins, possibly -receptor agonists, were shown to be inhibitory (Kanter et al. 1980; Green et al. 1980 ). Moreover, differences in concentrations of the peptides, as shown by Green et al. (1980) might also explain these differences. (Roemer et al. 1977 ).
The subjects were given a weight-maintaining diet containing at least 250 g carbohydrates for 3 days before the study. The sequences of the test were randomised and the tests were carried out at least at 1 week interval.
The tests were performed after an overnight fast. The subjects were placed in recumbent position. A short iv catheter (Venflon®) was introduced in an antecubital vein. Patency was maintained by means of a continuous iv infusion of saline.
After a 30 min rest, subjects of group A received an im injection of either 0.5 mg FK 33-824 in the thigh or of saline as placebo. Subjects of group ingested 100 g glucose dissolved in 400 ml water flavoured with lemon juice which they drank within 5 min after the im injection of either 0.5 mg FK 33-824 or saline, given at time 0 (OGTT). Similarly, subjects of group C were given an iv glucose load (0.5 g/kg body weight) as a 3 min infusion after the same im injection The mechanism involved in the inhibition of insulin secretion by the enkephalin-analogue FK 33-824 remains unknown, although it confirms in man some observations reported in the animal (Kanter et al. 1980; Green et al. 1980 ). The pre¬ sence of enkephalin has been reported in the pancreas and the gastro-intestinal track (Polak et al. 1977; Forsmann et al. 1977; Bruni et al. 1979 ).
Functional interactions have also been demon¬ strated between the opioid peptides and neurointe¬ stinal factors (Konturek et al. 1978a (Konturek et al. ,b, 1980 which could influence endocrine pancreatic secretion.
In conclusion, the present study shows that, in man, enkephalin produces a decrease in insulin secretion in response to glucose loads and suggests a possible role of the human endogenous opioid system in glucose tolerance. Moreover, the compa¬ rison between the oral and the iv results supports the hypothesis of an effect of enkephalin on glu¬ cose absorption.
